Patients’ characteristics after matched pairing of 109 patients with AML
| Modalities . | DDX41 WT (n = 77) . | DDX41 MUT (n = 32) . |
|---|---|---|
| Age at diagnosis | ||
| Median (IQR) | 58.2 (49.1-64.1) | 61.1 (49-64.2) |
| (Range) | (20-71.4) | (35.3-72.3) |
| Age at HSCT | ||
| Median (IQR) | 58.9 (49.5-64.7) | 61.5 (49.6-64.7) |
| (Range) | (20.6-71.8) | (36.2-72.6) |
| Months between diagnosis and HSCT | ||
| Median (IQR) | 5.4 (4.6-6.4) | 5.9 (5-6.6) |
| (Range) | (3-144.5) | (3.7-10) |
| Patient sex, n (%) | ||
| Female | 14 (18.2) | 6 (18.8) |
| Male | 63 (81.8) | 26 (81.2) |
| Female to male, n (%) | ||
| No | 56 (72.7) | 22 (68.8) |
| Yes | 21 (27.3) | 10 (31.2) |
| ELN status, n (%) | ||
| Int | 49 (63.6) | 22 (68.8) |
| Adv | 28 (36.4) | 10 (31.2) |
| Donor type, n (%) | ||
| MSD | 27 (35.1) | 10 (31.2) |
| MMRD | 4 (5.2) | 2 (6.2) |
| MUD | 39 (50.6) | 17 (53.1) |
| MMUD | 7 (9.1) | 3 (9.4) |
| Source of cells, n (%) | ||
| BM | 15 (19.5) | 6 (18.8) |
| PB | 62 (80.5) | 26 (81.2) |
| Myeloablative regimen, n (%) | ||
| No | 50 (64.9) | 23 (71.9) |
| Yes | 27 (35.1) | 9 (28.1) |
| TBI, n (%) | ||
| No | 63 (81.8) | 26 (81.2) |
| Yes | 14 (18.2) | 6 (18.8) |
| MAC TBI, n (%) | ||
| RIC | 50 (64.9) | 23 (71.9) |
| MAC chemo | 25 (32.5) | 7 (21.9) |
| MAC TBI | 2 (2.6) | 2 (6.2) |
| In vivo TCD, n (%) | ||
| No | 30 (39) | 11 (34.4) |
| ATG | 47 (61) | 21 (65.6) |
| GVHD prevention, n (%) | ||
| CSA | 13 (16.9) | 5 (15.6) |
| CSA+MMF | 27 (35.1) | 12 (37.5) |
| CSA+MMF+TACRO | 0 (0) | 0 (0) |
| CSA+MTX | 32 (41.6) | 13 (40.6) |
| MTX+MMF | 1 (1.3) | 0 (0) |
| PTCY+CSA | 1 (1.3) | 0 (0) |
| PTCY+CSA+MMF | 2 (2.6) | 1 (3.1) |
| Modalities . | DDX41 WT (n = 77) . | DDX41 MUT (n = 32) . |
|---|---|---|
| Age at diagnosis | ||
| Median (IQR) | 58.2 (49.1-64.1) | 61.1 (49-64.2) |
| (Range) | (20-71.4) | (35.3-72.3) |
| Age at HSCT | ||
| Median (IQR) | 58.9 (49.5-64.7) | 61.5 (49.6-64.7) |
| (Range) | (20.6-71.8) | (36.2-72.6) |
| Months between diagnosis and HSCT | ||
| Median (IQR) | 5.4 (4.6-6.4) | 5.9 (5-6.6) |
| (Range) | (3-144.5) | (3.7-10) |
| Patient sex, n (%) | ||
| Female | 14 (18.2) | 6 (18.8) |
| Male | 63 (81.8) | 26 (81.2) |
| Female to male, n (%) | ||
| No | 56 (72.7) | 22 (68.8) |
| Yes | 21 (27.3) | 10 (31.2) |
| ELN status, n (%) | ||
| Int | 49 (63.6) | 22 (68.8) |
| Adv | 28 (36.4) | 10 (31.2) |
| Donor type, n (%) | ||
| MSD | 27 (35.1) | 10 (31.2) |
| MMRD | 4 (5.2) | 2 (6.2) |
| MUD | 39 (50.6) | 17 (53.1) |
| MMUD | 7 (9.1) | 3 (9.4) |
| Source of cells, n (%) | ||
| BM | 15 (19.5) | 6 (18.8) |
| PB | 62 (80.5) | 26 (81.2) |
| Myeloablative regimen, n (%) | ||
| No | 50 (64.9) | 23 (71.9) |
| Yes | 27 (35.1) | 9 (28.1) |
| TBI, n (%) | ||
| No | 63 (81.8) | 26 (81.2) |
| Yes | 14 (18.2) | 6 (18.8) |
| MAC TBI, n (%) | ||
| RIC | 50 (64.9) | 23 (71.9) |
| MAC chemo | 25 (32.5) | 7 (21.9) |
| MAC TBI | 2 (2.6) | 2 (6.2) |
| In vivo TCD, n (%) | ||
| No | 30 (39) | 11 (34.4) |
| ATG | 47 (61) | 21 (65.6) |
| GVHD prevention, n (%) | ||
| CSA | 13 (16.9) | 5 (15.6) |
| CSA+MMF | 27 (35.1) | 12 (37.5) |
| CSA+MMF+TACRO | 0 (0) | 0 (0) |
| CSA+MTX | 32 (41.6) | 13 (40.6) |
| MTX+MMF | 1 (1.3) | 0 (0) |
| PTCY+CSA | 1 (1.3) | 0 (0) |
| PTCY+CSA+MMF | 2 (2.6) | 1 (3.1) |